Bio-IT World covers the first results of the AISB Network’s federated co-folding initiative and the launch of AISB Bind, a follow-on programme focused on predicting how molecules bind.
Affinity scores should depend on how a compound binds. ApherisAffinity uses structurally validated training data, a geometry-aware affinity head and disrupted-binding-site negatives, so its predictions respond to target changes and rank compounds in a real discovery series better than Boltz‑2 and Nesso‑1.
Apheris federated networks for drug discovery and European healthcare studies can now run on T-Systems’ sovereign infrastructure, with patient data staying inside each hospital.
AbbVie, argenx, Lundbeck and Takeda join Ginkgo Datapoints and Apheris as founding members of the Antibody Developability Consortium, building a standardised dataset of 10,000 antibodies.
NEWSLETTER
A quaterly briefing on operationalizing and customizing co-folding, ADMET and antibody developability models. Written by Robin Röhm, co-founder and CEO at Apheris.
